India’s generic GLP-1 drugs are (mostly) booming
By 
Anthony King2026-07-30T10:01:00
Manufacturing problems for some manufacturers have led to production pauses and recalled batches of diabetes and weight loss drugs
Patent protection for semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight loss drugs, has ended in several countries. This has stimulated a rush to introduce cheaper generic versions of Ozempic for diabetes and Wegovy for weight management – initially in India and Canada, but with several other countries soon to follow.